COMPANY
Saros Therapeutics Inc.
NIH awards 3
- NIH award 1R44CA306545-01A1 FY2026: $1,164,203 awarded for that fiscal year; activity R44 (SBIR); PI JOHNSON, RICHARD; recipient as written: SAROS THERAPEUTICS INC, CHICAGO, IL. Demonstrating safety and combination t source ↗
- NIH award 5R44CA281497-02 FY2024: $850,188 awarded for that fiscal year; activity R44 (SBIR); PI JOHNSON, RICHARD; recipient as written: SAROS THERAPEUTICS INC, CHICAGO, IL. Process Development and Preclinical Advanc source ↗
- NIH award 1R44CA281497-01A1 FY2023: $1,196,731 awarded for that fiscal year; activity R44 (SBIR); PI JOHNSON, RICHARD; recipient as written: SAROS THERAPEUTICS INC, CHICAGO, IL. Process Development and Preclinical Ad source ↗
Funding and NIH signals
- NIH award NIH awarded $1.16M (SBIR Phase II 1R44CA306545-01A1, new, notice Sep 1, 2026). NIH RePORTER 1R44CA306545-01A1 (Sep 1, 2026)
Evidence (1 event)
- Sep 1, 2026 · NIH RePORTER 1R44CA306545-01A1
Organization: SAROS THERAPEUTICS INC; City/State: CHICAGO, IL; Project number: 1R44CA306545-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1164203; Administering IC: National Cancer Institute; Project title: Demonstrating safety and combination therapy potential of a novel nanoparticle delivery system; Organization type: Domestic For-Profits
- Sep 1, 2026 · NIH RePORTER 1R44CA306545-01A1